Kobe University researchers identify treatment enhancing full-term pregnancy success in women with recurrent pregnancy loss linked to a specific self-targeting antibody.
Researchers from Kobe University have identified a treatment that enhances full-term pregnancy success in women with recurrent pregnancy loss linked to a specific self-targeting antibody. Published in Frontiers in Immunology, the study found that women receiving low-dose aspirin or heparin had an 87% live birth rate, compared to 50% for untreated women. Additionally, treatment reduced pregnancy complications from 50% to 6%, suggesting potential for broader applications in related conditions.
September 26, 2024
9 Articles